Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT04876131 · Complicated Urinary Tract Infection, Infection, and more
NCT05826990 · Complicated Urinary Tract Infection
NCT04335539 · Gram-negative Bacterial Infections, Bloodstream Infections (BSI), and more
NCT05887908 · Complicated Urinary Tract Infection, Acute Pyelonephritis, and more
NCT04215991 · Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), and more
Alabama Research Center
Birmingham, Alabama
Southeast Alabama Medical Center
Dothan, Alabama
Providence Hospital
Mobile, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions